PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Status Withdrawn

Clinical Trial Summary

This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced renal cancer. Blood samples will also be collected for research purposes.

Clinical Trial Description

This is a dose-escalation study of ex-vivo knocked-out, expanded, and selected PD-1 knockout-T cells from autologous origin. Patients are assigned to 1 of 3 treatment groups to determine the maximal tolerant dose. After the lower number of cycles are considered tolerant, an arm of the next higher number of cycles will be open to next patients. Biomarkers and immunological markers are collected and analyzed as well. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02867332
Study type	Interventional
Source	Peking University
Contact
Status	Withdrawn
Phase	Phase 1
Start date	November 2016
Completion date	November 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00930033` - Clinical Trial to Assess the Importance of Nephrectomy	Phase 3
Recruiting	`NCT05863351` - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study	Phase 3
Not yet recruiting	`NCT06284564` - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)	Phase 2
Completed	`NCT00414765` - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma	Phase 4
Active, not recruiting	`NCT03149822` - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT03647878` - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed	`NCT01517243` - Phase II Study of Alternating Sunitinib and Temsirolimus	Phase 2
Withdrawn	`NCT03927248` - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer	Phase 1/Phase 2
Terminated	`NCT02122003` - Second Line Sorafenib After Pazopanib in Patients With RCC	Phase 2
Completed	`NCT01182142` - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients	Phase 2
Completed	`NCT00630409` - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Completed	`NCT04076787` - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting	`NCT04467021` - Cancer and Blood Pressure Management, CARISMA Study	N/A
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT02282579` - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Completed	`NCT01731158` - Sequential Therapy in Metastatic Renal Cell Carinoma	Phase 2
Terminated	`NCT02071641` - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma	Phase 2
Terminated	`NCT01342627` - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT01274273` - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer	Phase 2